MicuRx(SH:688373) Zhong Guo Jing Ji Wang·2025-09-23 06:44Core Viewpoint - The company Mengke Pharmaceutical (688373.SH) has announced a plan to issue shares to a specific group, raising up to 1.03 billion yuan for daily research and operational investments [1][2]. Group 1: Share Issuance Details - The issuance price is set at 6.30 yuan per share, with a total of 163,901,373 shares to be issued [2]. - The recipient of the shares is Nanjing Haiqing Pharmaceutical Co., Ltd., which will acquire a 20% stake in Mengke Pharmaceutical, making it the controlling shareholder [2]. - Following the issuance, Haiqing Pharmaceutical will nominate 5 out of 9 board members, giving it majority control over the board [2]. Group 2: Financial Performance of Haiqing Pharmaceutical - Haiqing Pharmaceutical's revenue for 2022, 2023, and 2024 was 485.76 million yuan, 625.40 million yuan, and 648.25 million yuan, respectively, with net profits of 77.69 million yuan, 59.52 million yuan, and 103.84 million yuan [3][4]. - The company's total assets increased from 444.23 million yuan in 2022 to 633.04 million yuan in 2024, with a corresponding increase in equity [4]. Group 3: Mengke Pharmaceutical's Financial Performance - Mengke Pharmaceutical has reported revenues of 48.21 million yuan, 90.78 million yuan, and 130 million yuan for the years 2022 to 2024, with net losses of 220 million yuan, 421 million yuan, and 441 million yuan, respectively [7]. - In the first half of 2025, the company generated 66.97 million yuan in revenue, a year-on-year increase of 10.26%, but still reported a net loss of 139 million yuan [7].